A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Recruiting

Phase 3

Sponsor:

Hoffmann-La Roche

Code:

NCT04958265

Conditions

Atypical Hemolytic Uremic Syndrome

Eligibility Criteria

Sex: All

Age: 28 - 17

Healthy Volunteers: Not accepted

Interventions

Crovalimab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information